Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Eli Lilly and Company
LY-320,135
Другие языки:

    LY-320,135

    Подписчиков: 0, рейтинг: 0
    LY-320,135
    LY-320,135 Structure.svg
    Identifiers
    • 4-[6-methoxy-2-(4-methoxyphenyl)1-benzofuran-3-carbonyl]benzonitrile
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    ChEMBL
    ECHA InfoCard 100.190.302
    Chemical and physical data
    Formula C24H17NO4
    Molar mass 383.395 g·mol−1
    3D model (JSmol)
    • c3cc(OC)ccc3-c2oc1cc(OC)ccc1c2C(=O)c4ccc(C#N)cc4
    • InChI=1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3
    • Key:RYNSGDFWBJWWSZ-UHFFFAOYSA-N
      (verify)

    LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s.

    LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2, but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses.


    Новое сообщение